PulmCCM

Share this post

Tiotropium mist (Respimat) increases mortality risk, authors say

www.pulmccm.org

Discover more from PulmCCM

Life, death and the ICU
Over 39,000 subscribers
Continue reading
Sign in

Tiotropium mist (Respimat) increases mortality risk, authors say

...
Jun 11, 2011
Share this post

Tiotropium mist (Respimat) increases mortality risk, authors say

www.pulmccm.org
Share

Singh et al analyzed 5 randomized trials comparing tiotropium mist to placebo, and found a 46% relative increased risk of all-cause mortality among the treated arms. The Respimat inhaler is available in Europe, but the FDA has not approved it in the US. BMJ 2011;342:d3215.

Share this post

Tiotropium mist (Respimat) increases mortality risk, authors say

www.pulmccm.org
Share
Previous
Next
Comments
Top
New
Community

No posts

Ready for more?

© 2023 PulmCCM
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing